Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study

被引:6
作者
Roessler, Lucia [1 ]
Reich, Olaf [2 ]
Horvat, Reinhard [3 ]
de Souza, Sabrina Collas [4 ]
Holl, Katsyarina [5 ]
Joura, Elmar A. [1 ]
机构
[1] Med Univ Vienna, Dept Gynaecol & Obstet, Ctr Comprehens Canc, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Gynaecol & Obstet, A-1090 Vienna, Austria
[3] Med Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria
[4] GlaxoSmithKline Vaccines, Clin 4, Paris, France
[5] GlaxoSmithKline Vaccines, Wavre, Belgium
关键词
Epidemiology; Human papillomavirus; HPV high-risk types; Cervical dysplasia; Cervical cancer; HPV-16/18 AS04-ADJUVANTED VACCINE; CROSS-PROTECTIVE EFFICACY; OF-STUDY ANALYSIS; INTRAEPITHELIAL NEOPLASIA; PERINATAL-MORTALITY; PARTICLE VACCINE; HPV TYPES; WOMEN; DISEASE; CANCER;
D O I
10.1007/s00508-013-0403-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose is to present the Austrian data of an observational, cross-sectional, multicentre study conducted in 13 European countries. This study was undertaken to assess human papillomavirus (HPV) type distribution in high-grade cervical lesions. Two hundred and ninety cases of high-grade cervical intraepithelial neoplasia (CIN2, CIN3) or adenocarcinoma in situ of the cervix from 2004 to 2007 were analysed by histopathological review and polymerase chain reaction for HPV. Two hundred and nine cases were "histologically eligible" and of those 206 were HPV+. Median age was 34 years (19-76 years). CIN3 was the most frequent diagnosis (64.6 %), followed by CIN2/3 (19.4 %) and CIN2 (13.6 %). Adenocarcinoma in situ was only detected together with a squamous lesion in 2.4 % cases. Majority of women (75.2 %) were infected with a single HPV type, 98.1 % of them with high-risk HPV types: HPV 16 (56.1 %), HPV 33 (12.3 %), HPV 31 (11.0 %), HPV 18 (3.9 %), HPV 35 (3.9 %), HPV 51 (3.2 %) and HPV 52 (2.6 %), HPV 58 (1.9 %) and HPV 45 (0.6 %). The low-risk HPV 6 was found in 1.3 % cases. Forty-six lesions (22.3 %) contained multiple infections, 71.1 % of those were HPV 16 or 18 and 91.1 % were HPV 16, 18, 31, 33 or 45 positive. These Austrian data clearly demonstrate that HPV 16 is the predominant type in high-grade CIN, the immediate precursor lesions of cervical cancer. More than 60 % of the lesions were associated with HPV 16 and 18 and more than 85 % with HPV 16, 18, 31, 33 or 45. The prevalence of adenocarcinoma in situ is underestimated, since its detection is difficult with the current cytology screening.
引用
收藏
页码:591 / 599
页数:9
相关论文
共 50 条
  • [31] The role of human papillomavirus testing after treatment for high-grade cervical dysplasia
    Turner, Taylor B.
    Huh, Warner K.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 27 (01)
  • [32] Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era
    Oakley, Fredrick
    Desouki, Mohamed M.
    Pemmaraju, Manideepthi
    Gargano, Julia M.
    Markowitz, Lauri E.
    Steinau, Martin
    Unger, Elizabeth R.
    Zhu, Yuwei
    Fadare, Oluwole
    Griffin, Marie R.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2018, 55 (01) : 19 - 25
  • [33] MMP-9/RECK Imbalance: A Mechanism Associated with High-Grade Cervical Lesions and Genital Infection by Human Papillomavirus and Chlamydia trachomatis
    Discacciati, Michelle G.
    Gimenes, Fabrcia
    Pennacchi, Paula C.
    Faiao-Flores, Fernanda
    Zeferino, Luiz C.
    Derchain, Sophie M.
    Teixeira, Julio C.
    Costa, Maria C.
    Zonta, Marco
    Termini, Lara
    Boccardo, Enrique
    Longatto-Filho, Adhemar
    Consolaro, Marcia E. L.
    Villa, Luisa L.
    Maria-Engler, Silvya S.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (10) : 1539 - 1547
  • [34] HUMAN PAPILLOMAVIRUS INFECTION AFTER TREATMENT FOR HIGH-GRADE CERVICAL INTRAEPITHELIAL NEOPLASIA
    Shikova, E.
    Ivanova, Z.
    Zvirbliene, A.
    Ganchev, G.
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2012, 26 : 85 - 88
  • [35] Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study
    Wu, Shiqiang
    Ploner, Alexander
    Alsina, Ana Martina Astorga
    Deng, Yunyang
    Schollin, Lina Ask
    Lei, Jiayao
    LANCET REGIONAL HEALTH-EUROPE, 2025, 49
  • [36] Histomorphologic assessment and distribution of high-risk human papillomavirus (HPV) types in cervical high-grade squamous intraepithelial lesions with unusual histomorphologic features
    Gutnik, Helena
    Kastelic, Primoz
    Ostrbenk Valencak, Anja
    Poljak, Mario
    Strojan Flezar, Margareta
    VIRCHOWS ARCHIV, 2020, 476 (02) : 251 - 260
  • [37] Cervical Cancer Screening: Impact of Human Papillomavirus mRNA Testing on Detecting High-Grade Lesions in Women with Normal Cytology
    Strand, Ida-Marie
    Simonsen, Gunnar Skov
    Sorbye, Sveinung Wergeland
    WOMEN, 2024, 4 (03): : 290 - 302
  • [38] Distribution of human papillomavirus genotypes in women with high-grade cervical intraepithelial lesions and cervical carcinoma and analysis of human papillomavirus-16 genomic variants
    Karadza, Magdalena
    Lepej, Snjezana Zidovec
    Planinic, Ana
    Grgic, Ivana
    Corusic, Ante
    Planinic, Pavao
    Coric, Mario
    Hosnjak, Lea
    Komlos, Kristina Fujs
    Poljak, Mario
    Vince, Adriana
    CROATIAN MEDICAL JOURNAL, 2021, 62 (01) : 68 - 79
  • [39] Incidence of cervical high-grade squamous intraepithelial lesions and squamous cell carcinoma in women with high-risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype
    Gu, Liying
    Hong, Zubei
    Gao, Hua
    Qiu, Lihua
    Di, Wen
    CYTOPATHOLOGY, 2019, 30 (04) : 419 - 425
  • [40] Negative Pap tests in women with high-grade cervical lesions on follow-up biopsies: Contributing factors and role of human papillomavirus genotyping
    Goodman, Steven
    Mody, Roxanne R.
    Coffey, Donna
    Gorman, Blythe K.
    Luna, Eric
    Armylagos, Donna
    Schwartz, Mary R.
    Mody, Dina R.
    Ge, Yimin
    DIAGNOSTIC CYTOPATHOLOGY, 2018, 46 (03) : 239 - 243